Nuclear receptor LXR as a novel therapeutic antitumoral target in glioblastoma

Antonio Moschetta

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Both primary and transformed cells need cholesterol for their growth. Guo and colleagues unraveled the connection between epidermal growth factor receptor mutations in glioblastoma and increased cholesterol influx via sterol regulatory element-binding protein 1 and low-density lipoprotein receptor (LDLR) increase. They propose the activation of the liver X receptor-inducible degrader of LDLR-LDLR axis as a therapeutic approach to reduce intracellular cholesterol, block tumor growth, and induce cell death.

Original languageEnglish (US)
Pages (from-to)381-382
Number of pages2
JournalCancer discovery
Volume1
Issue number5
DOIs
StatePublished - Oct 1 2011

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Nuclear receptor LXR as a novel therapeutic antitumoral target in glioblastoma'. Together they form a unique fingerprint.

  • Cite this